Kerry M. Clem - 31 Mar 2023 Form 4 Insider Report for Acorda Therapeutics, Inc.

Role
Chief Commercial Officer
Signature
/s/ Kerry M. Clem
Issuer symbol
N/A
Transactions as of
31 Mar 2023
Net transactions value
$0
Form type
4
Filing time
04 Apr 2023, 16:40:33 UTC
Previous filing
07 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACOR Employee Stock Option (right to buy) Award $0 +77,300 $0.000000 77,300 31 Mar 2023 Common Stock 77,300 $0.5860 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on January 1, 2023 with the first quarterly installment vesting on April 1, 2023.